OnabotulinumtoxinA blockade of the sphenopalatine ganglion in treatment-resistant chronic migraine (MiBlock): rationale, design and study protocol for a multi-centre, investigator initiated, randomised, quadruple-blinded placebo-controlled trial.
Authors
Irina Aschehoug
Lise Rystad Øie (ORCID: https://orcid.org/0000-0001-9844-4651)
OnabotulinumtoxinA blockade of the sphenopalatine ganglion in treatment-resistant chronic migraine (MiBlock): rationale, design and study protocol for a multi-centre, investigator initiated, randomised, quadruple-blinded placebo-controlled trial.
Irina Aschehoug, Lise Rystad Øie, Erling Tronvik, Melanie Rae Simpson et al.
Journal
F1000Research
Topics
Migraine and Headache Studies
article
OnabotulinumtoxinA blockade of the sphenopalatine ganglion in treatment-resistant chronic migraine (MiBlock): rationale, design and study protocol for a multi-centre, investigator initiated, randomised, quadruple-blinded placebo-controlled trial.
Irina Aschehoug, Lise Rystad Øie, Erling Tronvik, Melanie Rae Simpson, Sozaburo Hara, Daniel Fossum Bratbak, Øyvind Salvesen, Einar Tobias Vassbø Skalstad, Tore Wergeland
article en
Abstract
No abstract available for this paper.
Publication Tag
F1000ResearchVol. 14
Institutions
Norwegian University of Science and Technology (NO), St Olav's University Hospital (NO)